

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1-40. (Cancelled).

41. (NEW) A surgical anti-adhesion patch made by the process of mixing a human cell capable of organizing a soluble collagen under conditions whereby the cells organize the soluble collagen into the patch in vitro.
42. (NEW) The anti-adhesion patch of claim 41, wherein the soluble collagen comprises at least one of type I collagen or type III collagen.
43. (NEW) The anti-adhesion patch of claim 41, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.
44. (NEW) The anti-adhesion patch of claim 41, wherein the collagen is from a natural source or a recombinant source.
45. (NEW) The anti-adhesion patch of claim 41, wherein the cells are autologous, heterologous, xenogeneic or engineered cells.
46. (NEW) The anti-adhesion patch of claim 41, wherein the cells are dermal fibroblasts or vascular smooth muscle cell.
47. (NEW) The anti-adhesion patch of claim 41, further comprising the step of removing the cells from the patch once the patch has been formed.
48. (NEW) The anti-adhesion patch of claim 41, wherein the patch further comprises a biocompatible bio-adhesive.
49. (NEW) The anti-adhesion patch of claim 41, wherein patch is adapted for use in thoracic cavity, abdominal cavity, ophthalmic system, orthopedic system, central nervous system, reproductive tract and an oral cavity.
50. (NEW) The anti-adhesion patch of claim 41, further comprising the addition of one or more growth factors selected from fibroblast growth factor (FGF), epidermal growth factor (EGF), platelet derived growth factor (PDGF), transforming growth factor beta (TGF β), transferrin, insulin and serum.
51. (NEW) A surgical anti-adhesion patch made by the process of mixing human

fibroblasts capable of organizing a soluble collagen in situ and in vitro under conditions whereby the cells organize the soluble collagen into the patch.

52. (NEW) The anti-adhesion patch of claim 51, wherein the soluble collagen comprises human type I collagen and human type III collagen.

53. (NEW) The anti-adhesion patch of claim 51, further comprising at least one of elastin, interstitial collagens, collagen type III, V and IX, glycoproteins or proteoglycans.

54. (NEW) The anti-adhesion patch of claim 51, wherein the collagen is from a natural source or a recombinant source.

55. (NEW) The anti-adhesion patch of claim 51, wherein the cells are autologous, heterologous, xenogenic or engineered cells.

56. (NEW) The anti-adhesion patch of claim 51, wherein the cells are dermal fibroblasts.

57. (NEW) The anti-adhesion patch of claim 51, further comprising the step of removing the cells from the patch once the patch has been formed.

58. (NEW) The anti-adhesion patch of claim 51, wherein the patch further comprises a biocompatible bio-adhesive.

59. (NEW) The anti-adhesion patch of claim 51, wherein patch is adapted for use in thoracic cavity, abdominal cavity, ophthalmic system, orthopedic system, central nervous system, reproductive tract and an oral cavity surgery.

60. (NEW) The anti-adhesion patch of claim 51, wherein patch is adapted for attach to the pericardium and prevents adhesions between the epicardium and the pericardium.